Dr. Michelle A. Baum, MD
Pediatric Nephrology (Pediatric Nephrology Physician)
At a glance
- Medical school
- Northwestern University Feinberg Medical School (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: Northwestern University Feinberg Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Nephrology Physician primary
MA license 77307 -
Pediatrics Physician
MA license 77307
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Boston Children's Hospital Boston, MA
Medical groups
- Children's Hospital Pediatric Associates, Inc (328 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 3 companies reported 4 payments worth $2,883 in total to this clinician.
| Novo Nordisk Inc | $1,800 |
|---|---|
| Alnylam Pharmaceuticals Inc. | $1,080 |
| Travere Therapeutics, Inc. | $3.32 |
| Consulting Fee | $2,880 |
|---|---|
| Education | $3.32 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Nov 8, 2025 | Consulting Fee | $1,800 |
| Alnylam Pharmaceuticals Inc. Feb 13, 2025 | Consulting Fee | $1,080 |
| Travere Therapeutics, Inc. Nov 12, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Dec 5, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $2,620 in research payments for these studies, mostly to the institutions running them.
- BONAPHIDE: A prospective observational study of patients with primary hyperoxaluria type 1 (PHI).
Alnylam Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.